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Abstract: Epigenetic changes are a hallmark of short- and long-term transcriptional regulation, and hence
instrumental in the control of cellular identity and plasticity. Epigenetic mechanisms leading to changes
in chromatin structure, accessibility for recruitment of transcriptional complexes, and interaction of
enhancers and promoters all contribute to acute and chronic adaptations of cells, tissues and organs
to internal and external perturbations. Similarly, the peroxisome proliferator-activated receptor 
coactivator 1 (PGC-1) is activated by stimuli that alter the cellular energetic demand, and subsequently
controls complex transcriptional networks responsible for cellular plasticity. It thus is of no surprise that
PGC-1 is under the control of epigenetic mechanisms, and constitutes a mediator of epigenetic changes
in various tissues and contexts. In this review, we summarize the current knowledge of the link between
epigenetics and PGC-1 in health and disease.
Keywords: peroxisome proliferator-activated receptor  coactivator 1 (PGC-1); exercise;
metabolism; epigenetics; histone modification; DNA methylation; micro RNA; gene regulation;
thermogenesis; metabolic diseases
1. Introduction
The term epigenetics originally described how phenotypic traits could be inherited without
alterations in the DNA sequence of the genome [1,2]. In recent years, this term has been expanded
and used in a more inclusive way to include non-heritable, even short-term plastic events. Often, the latter
are triggered by changes in the environment and drive the adaptations to external stimuli, e.g., those
exerted by exercise, fasting or high-fat diet [3–5]. In fact, in many of these contexts, epigenetic changes
are integral to an adequate transcriptional response, and dysregulation of such changes have been
linked to the etiology and/or pathology of various diseases. The peroxisome proliferator-activated
receptor  coactivator 1 (PPARGC1A, also called PGC-1) is a central regulator of mitochondrial
function and cellular metabolism, important for the adaptation of different tissues to increased energetic
demand [6,7]. Accordingly, the gene expression of PGC-1 is strongly regulated when phenotypic
changes of an organ require an increased production of ATP. Once activated, PGC-1 coordinates complex
and tissue-specific transcriptional networks that mediate cellular plasticity. Soon after its discovery,
epigenetic mechanisms have been linked to the action of PGC-1 as a transcriptional coactivator [8–10].
More recently, epigenetic changes have been identified to control the gene expression of PGC-1 in
physiological and pathological contexts [11–13]. In this review, we summarize the current understanding
of the epigenetic regulation of PGC-1 gene expression, and the epigenetic contribution to the activity of
the PGC-1-containing transcriptional complexes in health and disease.
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2. Epigenetic Mechanisms
Epigenetic regulation has originally been defined as heritable changes in gene expression that do
not involve DNA sequence alterations, hence mostly focused on DNA methylation and histone protein
modifications [1,2,14]. However, more recent work has clearly demonstrated that these and other
epigenetic changes can also occur short-term and in a transient manner. Thus, other mechanisms,
for example microRNAs (miRNAs), mRNA modifications, long non-coding RNAs (lncRNAs)
or nucleosome positioning are now included under the umbrella term epigenetics [15,16]. For many
of these, both stable as well as transient eects have now been demonstrated. Of note, many of
the recent insights have been made possible by the breakthrough advances in next generation
sequencing techniques.
2.1. Histone Modifications and Nucleosome Positioning
DNA strands are compacted in several layers into chromosomes, with the nucleosomes, the wrapping
of the DNA around eight core histones, as the first layer [17]. A condensed packaging is intrinsically
repressive in regard to the binding of transcription factors, and thereby prevents unwanted transcriptional
activity. Histone proteins can be posttranslationally modified at various residues, leading to changes
in the chromatin structure [18,19]. The integration of the consequences of methylation, acetylation,
phosphorylation and/or ubiquitination of histones thereby determines DNA accessibility for transcription
factors, the degree of condensation of the chromatin, or long-range interactions between distal regulatory
elements. Histone modifications can be stable as well as transient, the latter being an obligatory
event in transcriptional regulation of gene expression. Many of the histone modifying enzymes have
been identified, in particular those involved in histone acetylation (histone acetyl transferases, HATs)
and methylation. Histone acetylation events have been linked to relaxation of chromatin packing, and thus
facilitation of transcription factor and RNA polymerase binding [20]. The functional outcome of histone
methylation is more complex and dependent on the modification of specific sites [21]. Histone lysine
residues can be mono-, di- or tri-methylated, and act as activating or repressing marks. For example,
mono-methylation of lysine 9 or lysine 27 of histone 3 (H3K9 and H3K27) is generally associated with
transcriptional activation, di- or tri-methylated H3K4me2/3 with transcription factor binding regions
and increased gene expression, whereas mono-methylated H3K3me1 often marks enhancer regions,
and H3K27me3 or H3K9me3 are repressive marks [22,23]. For many of the known histone modifications,
the exact consequence is still unclear, and additional mechanisms have been proposed, e.g., regulation of
splicing or priming of promoters. Finally, histone modifications and DNA methylation events can act in
a cooperative manner, e.g., DNA methylation-promoted methylation of H3K9 [21].
Even though the nucleosome is a stable DNA-protein complex, nucleosomes can reposition on
the genomic DNA, a process called nucleosome sliding, which is independent of histone complex
disruption [24]. The CCCTC-binding factor (CTCF) anchors nucleosome positions and thereby
aects large transactivation domains (TADs). Moreover, nucleosome sliding is controlled by various
ATP-dependent chromatin remodeling proteins, for example the SWItch/Sucrose Non-Fermentable
(SWI/SNF) complex [25], leading to transcriptional activation such as large scale expression of
tissue-specific genes.
2.2. DNA Methylation
Most often, DNA methylation has been linked to silencing of transcription [26,27]. Methylation events
have primarily been described on the cytosine nucleotide, resulting in the formation of 5-methylcytosine
(5mC) [27]. Hydroxymethylation of cytosines (5hmC) has been considered as an intermediate step towards
demethylation. However, 5hmC marks are now recognized as an epigenetic marker [28]. Recently,
methylation of adenosine, as originally observed in bacterial genomes, has also been found and attributed
to functional outcomes in eukaryotic cells, potentially counteracting the effects of cytosine methylation [29].
Whole genome bisulfite sequencing has revealed that specific elements and regions exhibit marked
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differences in methylation events. For example, transposon-derived sequences are highly methylated in
the human genome, presumably as a mechanism to silence these elements. In contrast, regions with a high
CpG content, called CpG islands, can by hypomethylated, in particular when found in promoters or first
exons. CpG islands in intergenic regions may act as distal regulatory elements, or, in particular when found
in repeat regions, be important for chromosome stability [21,26,27]. Finally, CpG islands in gene bodies can
affect differential promoter usage, transcription elongation or splicing. The methylation event on cytosines
is mediated by a group of enzymes called DNA methyltransferases (DNMTs) [30]. Transcriptional
silencing is subsequently achieved by preventing transcription factor binding and the recruitment of 5mC
binding proteins, which in turn sequester histone deacetylases (HDACs). Inversely, DNA de-methylation
is exerted by Ten-eleven translocation methylcytosine dioxygenases (TETs), which play an important role
in the spatiotemporal control of opening genomic regions, e.g., in embryonic development [31].
2.3. miRNAs, lncRNAs, mRNA Modifications
Epigenetic changes might also be conferred by dierent types of RNAs [32]. miRNAs are small
RNAs, of around 22 nucleotides in length, which can interact with mRNAs and thus modulate
the activity of their targets in a posttranscriptional manner [33]. Long non-coding RNAs (lncRNAs)
aect cellular functions in a number of dierent ways, for example by aecting promoter activity
or mRNA translation [34]. Both types of RNAs not only act intracellularly, but are also delivered to other
cells via exosomal transport [35]. Moreover, an overlap between RNA activity and other epigenetic
mechanisms exists. In Arabidopsis, the miRNAs mir165 and mir166 are involved in the regulation
of DNA methylation [36]. Similarly, DNMT1, -3 and -3a are all predicted targets of miRNAs [37],
while miR-140 aects HDAC4 [38]. Furthermore, miR-132 fine-tunes circadian gene expression by
modulation of chromatin remodeling and protein translation [39]. Finally, mRNAs are also targets
for methylation events [40]. For example, the fat mass and obesity-associated protein (FTO) has been
strongly associated with human obesity, and acts as an N6-methyladenosine demethylase on mRNAs,
thereby aecting RNA metabolism and hence protein expression [41].
3. The Transcriptional Coactivator PGC-1
PGC-1 is a transcriptional coactivator that was initially identified in an interaction screen with
the nuclear receptor peroxisome proliferator-activated receptor  (PPAR) [42]. However, it is now
clear that PGC-1 binds to and coactivates a large number of dierent transcription factors, both of
the nuclear receptor superfamily as well as non-nuclear receptor-type of DNA binding proteins [6,43].
PGC-1 is the founding member of a small family of similar coactivator proteins, which also includes
PGC-1 and the PGC-1-related coactivator (PRC) [44]. The PGC-1 gene is transcribed from two
dierent promoters, and several transcript variants have been described, even though their exact
regulation and function remains to be elucidated [7]. In higher mammals, PGC-1 is expressed
in all tissue with a high energetic demand, e.g., brain, kidney, cardiac and skeletal muscle, brown
adipose tissue and liver [45]. In most of these organs, PGC-1 gene expression and post-translational
modifications are strongly regulated in a context-dependent manner, resulting in higher PGC-1
levels and activity upon internal and external stimuli that evoke an increased ATP demand, such
as fasting in the liver, physical activity in cardiac and skeletal muscle, or cold exposure in brown
adipose tissue [44,46]. Once activated, PGC-1 controls complex transcriptional networks that control
cellular plasticity, resulting in tissue-specific gene programs controlling hepatic gluconeogenesis,
thermogenesis in brown adipose tissue, or endurance exercise adaptation in skeletal muscle [6].
However, the core function of PGC-1 consists of the strong promotion of mitochondrial biogenesis
and function, coupled to enhanced oxidative phosphorylation of energy substrates [47,48].
As a transcriptional coactivator, PGC-1 contains no discernable DNA binding domain.
Moreover, no enzymatic activity has been attributed to this protein. Thus, mechanistically, PGC-1
relies on selective interaction with transcription factors to be recruited to target genes, and then serves
as a protein docking platform to recruit other complexes. For example, via N-terminal interaction,
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PGC-1 binds to HAT complexes by interacting with p300/cAMP-responsive element binding protein
(CREB), binding protein (CBP) and the sterol-receptor coactivator 1 (SRC-1) [8]. The ensuing acetylation
of histones contributes significantly to the transcriptional activation of PGC-1 target genes. Similarly,
recruitment of the thyroid hormone receptor-associated protein (TRAP)/vitamin D receptor interacting
protein (DRIP)/mediator complex to the C-terminus of PGC-1 facilitates the interaction of the PGC-1
transcriptional complex with RNA polymerase II [9]. Moreover, the direct interaction between PGC-1
and the PPAR interacting mediator subunit TRAP220 facilitates preinitiation complex formation
and function. Finally, PGC-1 binds to the BRG1-associated factor 60A (Baf60a), and thereby promotes
nucleosome remodeling and chromatin opening via SWI/SNF activity [10]. The recruitment of these
dierent complexes are linked. For example, a mutant version of PGC-1 lacking the C-terminal
domain not only lacks binding to the mediator complex, but also fails to enhance p300/CBP-dependent
transcription via the still intact N-terminus [9].
The strong transcriptional regulation of PGC-1 gene expression, and the recruitment of several
protein complexes that exert effects on histones and chromatin hint at a strong epigenetic control of
PGC-1 expression and action. In the following paragraphs, we have summarized the current knowledge
about the epigenetic regulation of PGC-1 in different physiological and pathophysiological contexts.
4. Regulation of Physiological PGC-1 Expression and Action by Epigenetic Mechanisms
4.1. Skeletal Muscle and Exercise
PGC-1 gene expression is strongly induced by multiple signaling pathways and stimuli in
the contracting muscle fiber (Figure 1) [6]. Interestingly, PGC-1 induces its own transcription in
a positive autoregulatory loop by coactivating myocyte enhancer factors 2 (MEF2) binding in the proximal
promoter region [49]. However, the PGC-1-mediated recruitment of HATs, and the resulting acetylation
of histones, competes in the absence of active protein kinase D (PKD) with binding of HDAC5 to
MEF2, which then mediates deacetylation of histones and transcriptional repression [50,51]. Indeed,
different histone marks have been linked to the transcriptional activity of PPARGC1A—the gene encoding
PGC-1—in skeletal muscle after exercise. For example, the expression of transcript isoforms that are
initiated from the distal promoter coincides with the deposition of the activation mark H3K4me3 one
hour after training in murine quadriceps muscle [52]. Similarly, elevated acetylation of histone 3 was
reported at the proximal promoter of rat PGC-1 in a muscle fiber type-dependent manner [53]. PGC-1
promoter activity furthermore is strongly influenced by DNA methylation events. In ex vivo stimulation
experiments of mouse soleus muscle, enhanced expression of PGC-1 after 180 minutes was preceded by
a decrease in DNA methylation at the promoter already after 45 minutes of stimulation [12]. In skeletal
muscle in vivo, a similar reduction in promoter methylation of the PGC-1 gene was associated with
elevated transcription [12]. Finally, a combination of H3K4me3 and H3K27me3 was found at the distal
promoter, indicative of a poised promoter ready for rapid transcriptional activation in skeletal muscle,
suggestive of the usage of poised promoters for isoform and tissue-specific expression of PGC-1 [52].
Then, the changes in DNA methylation in the PGC-1 promoter have been associated with nucleosome
repositioning in this locus. Thus, after an acute endurance exercise bout, the –1 nucleosome in the PGC-1
promoter is repositioned away from the transcriptional start site by exercise and hypomethylation of
the –260 nucleotide, leading to increased transcription of the PGC-1 gene [54]. Importantly, this
mechanism has been linked to decreased ectopic lipid deposition in muscle, but only in high responders
in regard to PGC-1 induction by exercise. Finally, the levels of muscle PGC-1 are affected by different
RNAs. For example, miR-23, a putative repressor of PGC-1, is strongly downregulated after 90 min of
acute exercise in mouse muscle [55]. In chronically trained and casted mice, the expression of miR-696
and PGC-1 negatively correlated with higher and lower expression of PGC-1 in training and unloading,
respectively [56]. The repressive effect of miR-696 on PGC-1 was subsequently confirmed in cultured
myocytes. Furthermore, the presence of an upstream open reading frame (uORF) in the 50 untranslated
region of PGC-1mediates translational repression in an evolutionary conserved manner [57]. Absence of
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a functional uORF in the genome of the Atlantic bluefin tuna correlates with high abundance of muscle
mitochondria, slow-twitch, oxidative muscle fibers, and an exceptionally high endurance.
In addition to the eects on PGC-1 gene expression, epigenetic mechanisms are involved in
modulating the activity of the PGC-1 protein in this tissue. For example, the coactivation of the nuclear
receptor estrogen-related receptor  (ERR) by PGC-1 correlates with the relative GC and CpG
content of ERR binding sites in PGC-1 target genes, implying a potential role of DNA methylation
in controlling the interaction between these two partners in the regulation of PGC-1-dependent
metabolic gene expression [58]. Second, as described above, by recruiting HAT, mediator and SWI/SNF
protein complexes, PGC-1 promotes various epigenetic changes to regulate a complex transcriptional
network [59]. Then, the nuclear receptor corepressor 1 (NCoR1) competes with PGC-1 for binding to
ERR, and represses PGC-1 target gene expression by recruiting HDAC complexes to the respective
regulatory sites [60]. Finally, the activity of PGC-1 is activated and repressed by deacetylation by sirtuin
1 (SIRT1) and acetylation by K(lysine) acetyltransferase 2A (Kat2a/Gcn5) [61], which are also involved
in the acetylation and, in the case of Kat2a, succinylation of histones. However, whether and how
posttranslational modifications of PGC-1 and histones by these enzymes are coordinated is unknown.
Of note, while many of these mechanisms up- and downstream of PGC-1 have been studied
and described in skeletal muscle, they might also be important for PGC-1 action in other tissues.
Figure 1. Overview of epigenetic changes on the peroxisome proliferator-activated receptor coactivator
1 (PGC-1) in skeletal muscle and exercise: a) In an inactive state, the promoter of PGC-1 is methylated
(MMM). PGC-1 induces its own transcription in a positive autoregulatory loop by coactivating
the myocyte enhancer factor 2 (MEF2); b) Protein kinase d (PKD) represses histone deacetylase
(HDAC) and retains the acetylation marks and elevation of PGC-1 transcription; (c) a combination of
trimethylation of histone 3 at lysine 4 (H3K4me3) and H3K27me3 is deposited at the distal promoter of
PGC-1 suggesting a fast switch of gene programs if necessary; d) nucleosome repositioning enhances
PGC-1 transcription; e) Micro RNA (miR)-696 and miR-23 are putative repressors of PGC-1; f) NCoR1
competes with PGC-1 for binding to estrogen-related receptor  (ERR), to repress PGC-1 target
gene expression; g) the activity of PGC-1 is activated and repressed by deacetylation by sirtuin 1
(SIRT1) and acetylation by K(lysine) acetyltransferase 2a (KAT2a).
4.2. Brown Adipose Tissue and Thermogenesis
Numerous studies with gain- and loss-of-function have underlined the central role of PGC-1
in controlling non-shivering thermogenesis in brown adipose tissue (Figure 2) [62]. Besides creatine
cycling, mitochondrial uncoupling is the major mechanism by which thermogenesis in brown adipose
tissue is achieved. Upon stimulation by -adrenergic signaling, the expression and activity of
the uncoupling protein 1 (UCP-1) is upregulated, which then produces heat by uncoupling the proton
gradient across the inner mitochondrial membrane from ATP production [63]. PGC-1 gene expression
is stimulated by -adrenergic signaling in brown adipocytes, and PGC-1 subsequently coactivates
PPAR and recruits SRC-1/p300 in regulatory elements of the UCP-1 gene to induce transcription [8,42].
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The regulation of PGC-1 gene expression in this context is mediated by dierent mechanisms. First,
the transcription factor ATF-2 is recruited to cAMP-responsive elements (CRE) in the PGC-1 promoter
upon phosphorylation by the p38 mitogen-activated protein kinase [64]. Second, in response to
-adrenergic signaling, HDAC1 association with the CRE element in the PGC-1 promoter is reduced
and replaced by binding of the H3K27 lysine-specific demethylase 6A (KDM6A) together with the HAT
CBP, leading to lower methylation and higher acetylation of H3K27 and subsequently enhanced
PGC-1 gene expression [65].
Figure 2. Regulation and activity of PGC-1 in the regulation of UCP-1 in brown adipose tissue
and thermogenesis: a) PGC-1 recruits peroxisome proliferator-activated receptor  (PPAR)
and sterol-receptor coactivator 1/E1A binding protein (SRC-1/p300) to regulatory elements of
the uncoupling protein 1 (UCP-1) gene; b) AMP-dependent transcription factor (ATF-2) is recruited to
cAMP response element (CRE) elements in the PGC-1 promoter upon phosphorylation by the p38
mitogen-activated protein kinase which enables PGC-1 transcription; c) Histone 3 lysine 27 (H3K27)
is demethylated by H3K27 lysine-specific demethylase 6A (KDM6A), higher acetylation of H3K27
subsequently leads to enhanced PGC-1 gene expression; d) interaction of PGC-1 with the JmjC
domain-containing histone demethylase 2 (JHDM2) aects the recruitment of the PPAR complex
containing retinoid X receptor  (RXR), PGC-1, p300 and SRC-1 to the PPAR-response elements
in the UCP-1 promoter; e) interaction of twist-related protein 1 (TWIST1) and PGC-1 represses
UCP-1 expression.
In addition to the regulation of PGC-1 gene expression in brown adipocytes, dierent epigenetic
mechanisms have been implied in the PGC-1-dependent regulation of UCP-1 expression in
thermogenesis [62]. First, PGC-1 interacts with the H3K9 JmjC domain-containing histone demethylase
2 (JHDM2), which aects the recruitment of the PPAR complex containing the heterodimerization
partner retinoid X receptor  (RXR), PGC-1, p300 and SRC-1 to the PPAR-response elements in
the UCP-1 promoter [66]. Consistently, JHDM2 knockout mice accumulate fat in adulthood and fail to
adapt to cold exposure, lacking adequate regulation of UCP-1 in brown fat tissue. PGC-1-mediated
induction of UCP-1 is also influenced by the twist-related protein 1 (TWIST1) [67]. While both proteins
are recruited to the UCP-1 promoter, TWIST1 associates with HDAC5, reduces PGC-1-induced
histone 3 acetylation and thereby represses the expression of UCP-1 and other target genes of PGC-1.
Interestingly, TWIST1 transcription is positively regulated by PPAR/, a transcription factor binding
partner for PGC-1 in the control of mitochondrial and other metabolic genes, and thereby exerts
a negative feedback loop on PGC-1 activity in brown adipose tissue.
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5. PGC-1 and Epigenetic Mechanisms in Disease
Many diseases are characterized by wide-spread epigenetic changes that could either contribute
to, or be a consequence of the pathological changes [68]. Similarly, dysregulation of mitochondria
is observed in numerous pathologies, often associated with changes in PGC-1 expression and/or
activity [69]. In the following sections, we have therefore summarized the current knowledge about
epigenetic mechanisms that control PGC-1 in dierent diseases (Figure 3).
5.1. Obesity
In skeletal muscle, obesity results in an altered gene expression profile that is associated with
wide-spread changes in DNA methylation events [13]. As one of these genes, the promoter of PGC-1
is hypermethylated in obese subjects, and the methylation pattern is restored after gastric bypass
surgery, comparable to that observed in lean individuals. Similar methylation changes of almost half of
the CpG sites in the PGC-1 promoter could be triggered by short-term overfeeding of young, healthy
men with a high fat diet in skeletal muscle [70], or of low-birthweight individuals in white adipose
tissue [70]. In the latter cohort, PGC-1 gene expression was restored after insulin injection. Changes in
the methylation status of the PGC-1 promoter were furthermore described in cultured human primary
myocytes exposed to fatty acids, in a DNMT3B-dependent manner [11]. A link between fatty acid
oxidation and PGC-1 promoter methylation was likewise proposed by the eect of decreased flavine
adenine dinucleotide (FAD) levels leading to a loss of histone 3 acetylation and H3K3me2/3 deposition
near the PGC-1 gene [71]. Of note, methylation of four specific CpG loci in the PGC-1 promoter in
blood of children was predictive of adiposity later in life, independent of sex, age, pubertal timing,
and activity [72].
5.2. Type II Diabetes
Hypermethylation of non-CpG sites at the PGC-1 promoter negatively correlated with PGC-1
expression in skeletal muscle of type 2 diabetic subjects compared to glucose-tolerant individuals [11].
This reduction was linked to DNMT3b activity in cultured myotubes treated with tumor necrosis factor
 (TNF) or free fatty acids, both leading to hypermethylation of the PGC-1 promoter. In particular,
the methylation site at –260 nucleotide location was responsible for the transcriptional repression in
that context. Moreover, a study in monozygotic twins showed higher methylation levels in the PGC-1
promoter in skeletal muscle and adipose tissue in type 2 diabetic subjects [73]. Similarly, a 2-fold
increase in PGC-1 promoter methylation was described in human pancreatic islet cells of type
2 diabetic individuals compared to normal individuals [74]. Finally, placental PGC-1 promoter
methylation correlated both with maternal hyperglycemia and newborn leptin levels [75].
5.3. Non-Alcoholic Fatty Liver Disease (NAFLD)
A comprehensive DNA methylation profiling of liver biopsies of morbidly obese patients with
NAFLD revealed broad changes in the methylation pattern compared to healthy individuals [76].
Motif prediction implied an enrichment in methylation changes in DNA regions of PGC-1
recruitment. Moreover, bariatric surgery reversed some of the NAFLD-associated methylation changes,
with a high enrichment of predicted binding sites for ERR, a strong interaction partner for PGC-1.
However, whether methylation changes modifying predicted PGC-1 and ERR recruitment sites really
contribute to the degree of NAFLD remains to be shown. In line with this hypothesis, NAFLD-related
insulin resistance is correlated positively with PGC-1 promoter methylation, and negatively with
PGC-1 gene expression [77].
5.4. Parkinson’s Disease
Adequate PGC-1 levels are indispensable for mitochondrial activity in the brain, and loss-of-function
of PGC-1 promotes neurodegenerative events in this organ [78,79]. In an extensive study incorporating
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322 samples from the brain and 88 samples from blood, non-canonical cytosine methylation of the PGC-1
gene was found to be significantly increased in Parkinson’s patients compared to controls [80]. In line,
treatment of mouse primary cortical neurons, microglia and astrocytes with palmitate caused PGC-1
promoter methylation at non-canonical cytosines. Likewise, the intracerebroventricular injection of
palmitate into mice with transgenic expression of human -synuclein triggered increased PGC-1
promoter methylation, reduced expression of PGC-1 and diminished the mitochondrial number in
the substantia nigra. Moreover, PGC-1 promoter methylation correlated with increased endoplasmatic
reticulum (ER) stress and inflammatory signaling.
5.5. Kidney Diseases
The lncRNA taurine-upregulated gene 1 (Tug1) interacts with PGC-1 in the kidney, and promotes
the binding of PGC-1 to its own promoter [81]. Activation of this mechanism in podocytes improves
mitochondrial function and reduces apoptosis as well as endoplasmic reticulum stress in diabetic
nephropathy [81,82]. In acute kidney injury, the TNF-related weak inducer of apoptosis (TWEAK)
stimulates HDAC recruitment to nuclear factor B (NF-B) on the PGC-1 promoter, resulting in
histone deacetylation and repression of PGC-1 gene transcription [83]. Thereby, an inflammatory
response is boosted while mitochondrial function is repressed in this pathological context.
Figure 3. Overview of the epigenetic changes on the PGC-1 in a pathological context: Increased
methylation of the PGC-1 promoter has been found to occur in obesity, diabetes, non-alcoholic fatty
liver disease (NAFLD) and Parkinson’s disease. Obesity and decreased flavin adenine dinucleotide
(FAD) levels lead to a loss of histone 3 acetylation and thus a decreased gene expression of PGC-1.
Exposure to TNF or FFA (free fatty acids) leads to a hypermethylation of the PGC-1 promoter
by the activation of DNA methyltransferase 3b (DNMT3b). In NAFLD, a decreased expression of
PGC1 target genes was associated with higher methylation of the respective promoters. In kidney
diseases, the micro RNA taurine upregulated gene (TUG1) promotes the binding of PGC-1 to its own
promoter. In acute kidney injury, histone deacetylase (HDAC) recruitment to nuclear factor B (NF-B)
on the PGC-1 promoter promotes deacetylation and thus repression of PGC1. Increased methylation
of the PGC-1 promoter has been found to occur in diabetes, NAFLD and Parkinson’s disease.
6. Conclusions and Perspectives
With the inclusion of transient, short-term changes, the traditional distinction between epigenetics
and transcriptional regulation becomes blurry. It is thus of little surprise that a strong transcriptional
regulator such as PGC-1 is not only controlled by, but also uses various epigenetic mechanisms to
modulate complex transcriptional networks in acute settings. The more persistent changes in PGC-1
promoter methylation in numerous diseases however hint at a more long-term control of PGC-1 to be
important for health and disease. Future studies will hopefully aim at elucidating these eects not only
in the pathological, but also physiological context. For example, even though clear evidence exists,
the hereditary aspects of exercise training remain enigmatic [5,84]. Intriguingly, the selection of high-
and low-capacity runners of rats demonstrated the heritability of treadmill exercise, and was associated
with higher PGC-1 protein levels in the muscles of high- compared to low-capacity runners [85]. It will
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be interesting to study whether epigenetic regulation of PGC-1 underlies this eect. These and other
similar studies will ultimately help to understand cell plasticity over dierent time scales in health
and disease.
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